The use of innovative treatments such as chimeric antigen receptor (CAR) T-cell therapy is rapidly expanding. More centers are developing dedicated programs for the delivery of this therapy, but in its early days, the learning curve could be steep. The challenges of receiving and delivering this novel therapy were discussed at the NCCN 2019 Annual Conference’s keynote session. In a separate roundtable discussion, additional stakeholders discussed how payers and providers are grappling with the cost of incorporating CAR T-cell therapy into practices (for more on the NCCN Roundtable, “Emerging Issues in Oncology,” see https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1512; video is available at https://youtu.be/z9qG_8ue6jM).
Sharing perspectives on CAR T-cell therapy at the NCCN 2019 Annual Conference were Jeffrey Backer, MD, a doctor at Emergency Physicians of Central Florida and who was also a patient, and 2 members of his treatment team at Moffitt Cancer Center: Frederick L. Locke, MD, Vice Chair and Associate Member of the Department of Blood and Marrow Transplant and Cellular Immunotherapy, and Alix Beaupierre, BSN, RN, OCN, Blood and Marrow Transplantation and Cellular Immunotherapy Nurse Coordinator.
Dr. Locke also participated in the discussion of costs in an NCCN Roundtable moderated by Clifford Goodman, PhD, Senior Vice President at The Lewin Group, a national healthcare and human services consulting firm. Dr. Goodman elicited perspectives as well from John W. Sweetenham, MD, Executive Medical Director and Senior Director for Clinical Affairs at the Huntsman Cancer Institute at the University of Utah; Lalan S. Wilfong, MD, Executive Vice President for quality programs and value-based care for Texas Oncology and physician liaison for value-based care for McKesson Specialty Health; Stefanie Joho, research/patient advocate and consultant; and Jennifer Malin, MD, PhD, Senior Medical Director of Oncology and Genetics at United Health Group.
Disclosures: Dr. Backer has disclosed that he has no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. Dr. Locke has disclosed that he has served as a scientific advisor for Kite/Gilead Sciences, Inc. and Novartis Pharmaceuticals Corporation and has received consulting fees from Cellular Biomedicine. Ms. Beaupierre has disclosed that she served on the product/speakers bureau for Kite Pharma. The remaining participants have no disclosures.